INVO Fertility, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. The company operates in two divisions, NAYA Women's Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as solid and pediatric tumors; and NY-338, a CD38-targeted FLEX-NK bispecific antibody for multiple myeloma and autoimmune diseases. The company also offers INVOcell, a a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025. INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.